This grant is a resubmission of a Core grant request for the University of Michigan Cancer Center. The application has been revised based on the suggestions of the previous NCI Center Support Review Committee. The University of Michigan Cancer Center (UMCC) was established by the Board of Regents in May 1986 to provide a focus for all of the cancer related activities throughout the University. The strategy of the Cancer Center is to provide an organizational framework to promote and enhance interdisciplinary research throughout the University. This is accomplished through the development of defined clinical and basic science interdisciplinary programs in cancer research and the development and support of shared core resources. There are seven clinical research programs in the UMCC. These represent coordinated research efforts in cancers of major organ systems including head and neck, breast, chest, genito-urinary, central nervous system, leukemia and lymphoma, and pediatric tumors. The six basic science research programs of the Center include tumor metastasis and the extracellular matrix, molecular mechanisms of gene regulation, tumor immunology, cancer pharmacology, drug development, and cancer epidemiology causation and prevention. The UMCC has established 10 shared core facilities which include a clinical trials office, biostatistics, tissue procurement, tumor imaging, pharmacokinetics, drug analysis, molecular biology, peptide synthesis, morphology and cytometry cores. The University has committed significant resources to the Cancer Center for the support of Center programs and shared core facilities. Dr. Wicha, Center Director, has responsibility for managing the affairs of the Center. He has authority and responsibility for space, equipment, budgets, and personnel assigned to the Center in addition to responsibility for coordinating Center Basic Research and Clinical Research Programs. The 216 faculty with appointments to the UMCC currently receive over 21 million dollars annually in grant support. The UMCC has had a major impact on cancer research at the University of Michigan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-08
Application #
2092232
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-09-30
Project End
1996-05-31
Budget Start
1995-09-06
Budget End
1996-05-31
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications